JP2024521765A - 勃起不全を治療するための製剤および方法 - Google Patents

勃起不全を治療するための製剤および方法 Download PDF

Info

Publication number
JP2024521765A
JP2024521765A JP2023572709A JP2023572709A JP2024521765A JP 2024521765 A JP2024521765 A JP 2024521765A JP 2023572709 A JP2023572709 A JP 2023572709A JP 2023572709 A JP2023572709 A JP 2023572709A JP 2024521765 A JP2024521765 A JP 2024521765A
Authority
JP
Japan
Prior art keywords
formulation
vardenafil
solubility
sildenafil
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572709A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022250731A5 (https=
JP2024521765A5 (https=
Inventor
モーゼ チャウ
シェリル エル． チャウ
Original Assignee
ストラテジック ドラッグ ソリューションズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ストラテジック ドラッグ ソリューションズ， インコーポレイテッド filed Critical ストラテジック ドラッグ ソリューションズ， インコーポレイテッド
Publication of JP2024521765A publication Critical patent/JP2024521765A/ja
Publication of JPWO2022250731A5 publication Critical patent/JPWO2022250731A5/ja
Publication of JP2024521765A5 publication Critical patent/JP2024521765A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023572709A 2020-05-26 2021-12-01 勃起不全を治療するための製剤および方法 Pending JP2024521765A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063029881P 2020-05-26 2020-05-26
USPCT/US2021/034334 2021-05-26
PCT/US2021/034334 WO2021242913A1 (en) 2020-05-26 2021-05-26 Formulations and methods for treating erectile dysfunction
PCT/US2021/061488 WO2022250731A1 (en) 2020-05-26 2021-12-01 Formulations and methods for treating erectile dysfunction

Publications (3)

Publication Number Publication Date
JP2024521765A true JP2024521765A (ja) 2024-06-04
JPWO2022250731A5 JPWO2022250731A5 (https=) 2024-12-10
JP2024521765A5 JP2024521765A5 (https=) 2024-12-10

Family

ID=78722740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572709A Pending JP2024521765A (ja) 2020-05-26 2021-12-01 勃起不全を治療するための製剤および方法

Country Status (10)

Country Link
US (1) US20240216383A1 (https=)
EP (1) EP4157449A4 (https=)
JP (1) JP2024521765A (https=)
KR (1) KR20240013128A (https=)
CN (1) CN116568289A (https=)
AU (1) AU2021280285A1 (https=)
BR (1) BR112022024098A2 (https=)
CA (1) CA3179630A1 (https=)
IL (1) IL298432A (https=)
WO (2) WO2021242913A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL247528B1 (pl) * 2023-04-08 2025-07-21 Sativa Med Spolka Akcyjna Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035926A2 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
JP2004525968A (ja) * 2001-04-12 2004-08-26 バイエル アクチェンゲゼルシャフト 鼻適用のためのイミダゾトリアジノン含有の組成物
JP2008531614A (ja) * 2005-03-01 2008-08-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト 改良された薬物動態学的特性を有する製剤
JP2015511213A (ja) * 2011-12-21 2015-04-16 ロンドンファーマ リミテッド 薬物送達技術
US20170014417A1 (en) * 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
US20060207596A1 (en) * 2005-03-18 2006-09-21 Fairfield Clinical Trials, Llc Device and method for delivery of combination nasal medication
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
MX2010004265A (es) * 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
US20140271847A1 (en) * 2013-03-13 2014-09-18 SatisPharma, LLC Formulations and methods for rapid penile erections
CN111655229A (zh) * 2017-12-20 2020-09-11 卡里亚制药控股有限公司 包含伐地那非的薄膜制剂、其制备方法及其用途
US11648197B2 (en) * 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035926A2 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
JP2004525968A (ja) * 2001-04-12 2004-08-26 バイエル アクチェンゲゼルシャフト 鼻適用のためのイミダゾトリアジノン含有の組成物
US20040248891A1 (en) * 2001-04-12 2004-12-09 Bayer Aktiengesellschaft Imidazotriazinone-containing compositions for nasal administration
JP2008531614A (ja) * 2005-03-01 2008-08-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト 改良された薬物動態学的特性を有する製剤
JP2015511213A (ja) * 2011-12-21 2015-04-16 ロンドンファーマ リミテッド 薬物送達技術
US20170014417A1 (en) * 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AAPS PHARMSCITECH, vol. 10, no. 2, JPN6026000135, 2009, pages 361 - 367, ISSN: 0005775455 *

Also Published As

Publication number Publication date
CA3179630A1 (en) 2021-12-02
WO2021242913A1 (en) 2021-12-02
IL298432A (en) 2023-01-01
EP4157449A1 (en) 2023-04-05
BR112022024098A2 (pt) 2023-02-07
WO2022250731A1 (en) 2022-12-01
US20240216383A1 (en) 2024-07-04
KR20240013128A (ko) 2024-01-30
CN116568289A (zh) 2023-08-08
AU2021280285A1 (en) 2023-02-02
EP4157449A4 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
ES2664776T3 (es) Composición farmacéutica anticonvulsiva transnasal que comprende anticonvulsivo poco soluble
UA59385C2 (uk) Інтраназальна композиція для лікування сексуальних розладів
CN101181241A (zh) 用于鼻内给药的芬太尼组合物
JP2018516989A (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
ZA200602134B (en) Methods and compositions for the oral adminstration of prodrugs of proton pump inhibitors
ZA200407672B (en) Low dose liquid entecavir formulations and use.
JP2024521765A (ja) 勃起不全を治療するための製剤および方法
JP5288211B2 (ja) 経鼻抗けいれん医薬組成物
HK40098632A (zh) 治疗勃起功能障碍的配方和方法
Patel et al. Spectrophotometric method for estimation of rabeprazole.
CN1977846A (zh) 治疗阳痿的药物组合物
JP2001163776A (ja) 安定化された液剤
WO2024141623A1 (en) Liquid pharmaceutical formulations of quinolines
JP2016540748A (ja) オンダンセトロン舌下スプレー製剤
CN101484132A (zh) 具有合意口味的雷尼替丁制剂
US20250064830A1 (en) Transdermal treatment for erectile dysfunction
US20050075371A1 (en) Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20190117624A1 (en) Therapeutic agent for inflammatory bowel diseases
WO2026043819A1 (en) Formulations and methods for convenient and rapid diuresis for the treatment of edema
PL247528B1 (pl) Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji
JP2017523231A (ja) 癌治療用アファチニブ医薬キット
CN101184486A (zh) 口服质子泵抑制剂前体药物的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420